Table 6.
Top canonical responses to LPS modified by A2AAR KO (the 15 most promoted or inhibited by A2AAR KO are shown)
| Canonical Pathways | P value | Ratio | Genes |
|---|---|---|---|
| LPS responses enhanced by A2AR KO (countered by A2AR activity) | |||
| Acute phase response signalling | 7.41E-04 | 5.06E-02 | Hpx, Hp, Rras2, Pik3r1, Cp, Il6, Serpine1, Nr3c1, Orm1 |
| Glucocorticoid receptor signalling | 9.33E-04 | 3.90E-02 | Hspa4, Cxcl3, Rras2, Pik3r1, Cdkn1a, Tgfb2, Il6, Stat1, Serpine1, Hspa2, Nr3c1 |
| Glioma invasiveness signalling | 1.29E-03 | 8.47E-02 | Timp4, Rras2, Pik3r1, Rhoj, Itgb3 |
| Germ cell-sertoli cell junction signalling | 1.45E-03 | 5.00E-02 | Rras2, Tuba8, Pak6, Map3k6, Pak3, Pik3r1, Tgfb2, Rhoj |
| Angiopoietin signalling | 3.16E-03 | 6.58E-02 | Grb14, Rras2, Pak6, Pak3, Pik3r1 |
| ILK signalling | 3.55E-03 | 4.26E-02 | Ppp2r3a, Pik3r1, Vegfc, Atf4, Rhoj, Itgb6, Pgf, Itgb3 |
| Ephrin receptor signalling | 3.98E-03 | 4.04E-02 | Rras2, Pak6, Pak3, Vegfc, Atf4, Epha4, Efnb3, Pgf |
| ERK/MAPK signalling | 4.37E-03 | 4.10E-02 | Rras2, Pak6, Pak3, Ppp2r3a, Ppp1R3c, Pik3r1, Atf4, Stat1 |
| Pancreatic adenocarcinoma signalling | 4.47E-03 | 5.08E-02 | Pik3r1, Cdkn1a, Tgfb2, Vegfc, Stat1, Pgf |
| HER-2 signalling in breast cancer | 5.13E-03 | 6.17E-02 | Rras2, Pik3r1, Cdkn1a, Itgb6, Itgb3 |
| Macrophage NO & ROS production | 7.08E-03 | 3.74E-02 | Map3k6, Ppp2r3a, Ppp1r3c, Pik3r1, Rhoj, Irf8, Stat1 |
| Hepatic fibrosis/stellate cell activation | 1.05E-02 | 4.48E-02 | Cxcl3, Tgfb2, Vegfc, Il6, Stat1, Pgf |
| Circadian rhythm signalling | 1.12E-02 | 8.57E-02 | Per3, Arntl, Atf4 |
| HIF1α signalling | 1.38E-02 | 4.55E-02 | Rras2, Pik3r1, Vegfc, Slc2a4, Pgf |
| JAK/Stat signalling | 1.41E-02 | 6.06E-02 | Rras2, Pik3r1, Cdkn1a, Stat1 |
| LPS responses inhibited by A2AR KO (promoted by A2AR activity) | |||
| PXR/RXR activation | 6.46E-04 | 4.4E-02 | Rac2, Prkar2b, Cyp2b6 |
| Nicotinate and nicotinamide metabolism | 3.98E-03 | 2.94E-02 | Cilp, Art5, Eif2ak2, Bst1 |
| Amyloid processing | 4.57E-03 | 5.08E-02 | Rac2, Prkar2b, Capn10 |
| Glutamate receptor signalling | 5.89E-03 | 4.29E-02 | Glul, Slc38a1, Homer1 |
| AMPK signalling | 9.55E-03 | 2.40E-02 | Rac2, Prkar2b, Adipoq, Eif4ebp1 |
| PRRs in recognition of bacteria & viruses | 9.77E-03 | 3.66E-02 | C3, Ddx58, Eif2ak2 |
| NF-κB signalling | 1.15E-02 | 2.58E-02 | Rac2, Nfkbie, Btrc, Eif2ak2 |
| NF-κB activation by viruses | 1.23E-02 | 3.61E-02 | Rac2, Nfkbie, Eif2ak2 |
| Inhibition of angiogenesis by TSP1 | 1.55E-02 | 5.56E-02 | Rac2, Sdc1 |
| Role of RIG1-like receptors in antiviral innate immunity | 1.66E-02 | 3.92E-02 | Nfkbie, Ddx58 |
| FXR/RXR activation | 1.78E-02 | 2.91E-02 | Rac2, Sdc1 |
| TR/RXR activation | 1.78E-02 | 3.03E-02 | Rac2, Ucp1 |
| PPARα/RXRα activation | 1.86E-02 | 2.22E-02 | Prkar2b, Nfkbie, Adipoq |
| RANK signalling in osteoclasts | 1.95E-02 | 3.06E-02 | Rac2, Nfkbie, Map3k2 |
| Fcγ receptor-mediated phagocytosis in macrophages and monocytes | 2.04E-02 | 2.97E-02 | Hmox1, Rac2, Hck |
Canonical pathways modified by LPS, ranked according to P-values determined by Fisher’s Exact Test. Also shown is the ratio reflecting the number of molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in the path